Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 4, 2015
Pharmacy Choice - News - U.S. Pharmaceutical Industry - March 4, 2015

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

3/4/15 - Adamis Announces Positive Results For Its Dry Powder Inhaler Product; Biota Commences Dosing in Vapendavir SPIRITUS Phase 2b Trial
Below is a look at some of the headlines for companies that made news in the healthcare sector on March 3, 2015.{ nfg} Adamis Pharmaceuticals Corporation announced the results of its pharmacokinetic study for its dry powder inhaler product, APC-5000. The study was a Phase I PK study comparing the bioavailability of Adamis' APC-5000 Dry Powder Inhal
3/3/15 - Actelion's New Drug Application for selexipag (Uptravi) is accepted by the US FDA with a standard review time
Actelion Pharmaceuticals Ltd/ Actelion's New Drug Application for selexipag is accepted by the US FDA with a standard review time. ALLSCHWIL, SWITZERLAND- 03 March 2015- Actelion Ltd today announced the formal acceptance of the New Drug Application for selexipag by the US Food and Drug Administration. Jean-Paul Clozel, M.D. and Chief Executive Offi
3/3/15 - ADAMAS PHARMACEUTICALS INC - 10-K - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You should read the following discussion and analysis of our financial condition and results of operations together with the section of this report entitled "Selected financial data" and our financial statements and related notes included elsewhere in this report. This discussion and other parts of this report contain forward-looking statements tha
3/3/15 - Adamas Reports Fiscal 2014 Financial Results
Adamas Pharmaceuticals, Inc. today reported financial results for the year ended December 31, 2014. Adamas reported net income attributable to common stockholders of $9.1 million, or $0.53 per share, for the fiscal year ended December 31, 2014. Adamas ended the year with $158.7 million in cash, cash equivalents, and marketable securities compared
3/3/15 - Aerie Pharmaceuticals to Participate in Two Investor Conferences in March
IRVINE, Calif., BEDMINSTER, N.J.& RESEARCH TRIANGLE PARK, N.C. Aerie Pharmaceuticals, Inc. a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today that Vicente Anido, Jr., Ph.D., Chie
3/3/15 - Aldeyra Provides Update on NS2 Clinical Program; Acasti Receives Full Data for Phase II TRIFECTA Trial
Below is a look at some of the headlines for companies that made news in the healthcare sector on March 2, 2015.{ nfg} Aldeyra Therapeutics, Inc., provided an update on its planned clinical trial programs in noninfectious anterior uveitis and Sjgren-Larsson Syndrome, as part of its webcast presentation at the Cowen and Company 35th Annual Healthc
3/3/15 - AMARIN CORP PLC\UK - 10-K - Management's Discussion and Analysis of Financial Condition and Results of Operations
These statements include but are not limited to statements regarding the commercial success of Vascepa in its first approved indication, the MARINE indication;, the potential for, conditions to, and timing of, approval of the Vascepa Supplemental New Drug Application, or sNDA, by the United States Food and Drug Administration, or FDA, in its potent
3/3/15 - Amarin Reports Fourth Quarter and Year-End 2014 Financial Results and Provides Update on Operations
BEDMINSTER, NJ and DUBLIN, IRELAND 03/03/15 Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter and year ended December 31, 2014, and provided an update on company operations. Key Amarin achievem
3/3/15 - Amicus Therapeutics Announces Full-Year 2014 Financial Results and Corporate Updates
Amicus Therapeutics, a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced financial results for the full-year ended December 31, 2014. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, "Our vision at Amicus is very clear: to build one of the most signific
3/3/15 - AMICUS THERAPEUTICS INC - 10-K - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
We are a biopharmaceutical company focused on the discovery, development and commercialization of next-generation medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders. Our lead product candidate is a small molecule that can be used as a monotherapy and in combination with enzyme repla
3/3/15 - Aquinox Pharmaceuticals Completes Enrollment in the Phase 2 LEADERSHIP Trial of AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis [Saudi Press Agency (Saudi Arabia)]
-Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today announced that it has reached its target enrollment in the Phase 2 LEADERSHIP trial of AQX-1125 for the treatment of bladder pain syndrome/interstitial cystitis.
3/3/15 - Arena Pharma Q4 Loss Widens, Misses View
The San Diego, California- based company reported a net loss of $32.06 million or $0.15 per share for the fourth quarter, wider than $23.46 million or $0.11 per share in the prior-year quarter. Revenues included $3.8 million in net product sales of obesity drug Belviq, of which $3.2 million represented 31.5 percent of Japanese drugmaker Eisai Co. L
3/3/15 - Athersys teams with Chugai Pharmaceutical to develop cell therapy in Japan [EMBIN (Emerging Markets Business Information News]
Cleveland biotech company Athersys Inc. said it has formed a partnership and licensing agreement with Chugai Pharmaceutical Co. to develop and commercialize Athersys' MultiStem cell therapy for ischemic stroke in Japan. In a joint news release, the companies said Chugai will be responsible for the development and commercialization of MultiStem for.
3/3/15 - AtriCure to Present at the Barclays Capital Global Healthcare Conference
AtriCure, Inc., a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Barclays Capital Global Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, Florida on Tuesday, March 10, 2015. AtriCure, Inc. is a medical device company providing inn
3/3/15 - BioPharmX Corporation To Present At 27th Annual Roth Capital Partners Conference On March 11, 2015
BioPharmX Corporation, a specialty pharmaceutical company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced that Jim Pekarsky, chief executive officer and co-founder of BioPharmX, will present at the 27 th Annual Roth Capital Partners Conference on Wed
3/3/15 - BioShares ETFs to Ring The Nasdaq Stock Market Opening Bell
The BioShares TM Biotechnology Clinical Trials Fund and the BioShares TM Biotechnology Products Fund, began trading on The Nasdaq Stock Market on December 17, 2014. In honor of the occasion, Paul Yook, Co-Founder of LifeSci Index Partners and Andrew MacDonald, Ph.D, Chief Executive Officer of LifeSci Index Partners will ring the Opening Bell.
3/3/15 - Canadian Cannabis Corporation Expands Operations in Ontario-Set to Acquire Majority Stake in Hemisphere Pharmaceutical
Canadian Cannabis Corporation today announced the execution of a Letter of Intent that provides for the acquisition of 60% of the outstanding shares in 8455562 Canada Inc. d/b/a Hemisphere Pharmaceutical based in Brantford, Ontario. Both companies are currently being reviewed by Health Canada. On February 2, 2014, HPI reached a milestone when it re
3/3/15 - CASI Pharmaceuticals To Present At The 27th Annual ROTH Conference
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announces that Ken K. Ren, Ph.D., CASI's Chief Executive Officer, will be making a corporate pres
3/3/15 - Clinical Study Published in Neurology Finds That electroCore's Non-Invasive Vagus Nerve Stimulation is Effective in Treating Cluster Headaches
A twelve-month open-label study in the March issue of the journal Neurology, reports that electroCore s non-invasive Vagus Nerve stimulation device, gammaCore, is practical and effective as an acute and preventative treatment in cluster headache. The study into cluster headache, which is considered to be one of the most painful conditions known
3/3/15 - Columbia Laboratories to Present at the 27th Annual ROTH Conference
Columbia Laboratories, Inc., a specialty pharmaceutical company focused on pharmaceuticals for women's health, today announced that it will present at the 27th Annual ROTH Conference, which will take place from March 8-11 at the Ritz-Carlton Laguna Niguel in Dana Point, California. Columbia Laboratories, Inc. has a successful heritage in developi
3/3/15 - Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that it intends to offer shares of common stock in a public offering. The offering will be made in the United States only by means of a
3/3/15 - Dara BioSciences Announces Fourth Quarter and Full Year 2014 Results
DARA BioSciences, Inc., an oncology supportive care pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its financial results for the fourth quarter and full year ended.
3/3/15 - DARA BIOSCIENCES, INC. - 10-K - Management's Discussion and Analysis of Financial Condition and Results of Operations.
Through our acquisition of Oncogenerix, Inc., which occurred on January 17, 2012, we acquired exclusive U.S. marketing rights to our first commercial FDA- approved proprietary product license, Soltamox? oral solution. Soltamox has been approved by the U.S. Food and Drug Administration for the prevention and treatment of breast cancer. On September
3/3/15 - DelMar Pharmaceuticals to Present at the 27th Annual ROTH Conference on March 10, 2015
VANCOUVER, British Columbia and MENLO PARK, Calif., March 3, 2015/ PRNewswire/ DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that it will be presenting at the 27th Annual ROTH Conference being held March 8-11, 2015, at The
3/3/15 - Depomed To Present At 27th Annual Roth Conference
Depomed, Inc. today announced that it will be presenting at the 27 th Annual Roth Conference in Laguna Niguel, California. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. Depomed is a specialty pharmaceutical company that commercializes products for pain
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Lupus: What You Need to Know
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part II: Psychiatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415